Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Albiges

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 5, 2021
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignanciesF Pommeret, J Colomba, C Bigenwald, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]C Dariane, C Pasqualini, N Gaspar, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 17, 2016
[CCAFU french national guidelines 2016-2018 on renal cancer]K Bensalah, L Albiges, J-C Bernhard, et al.
ESMO Open|December 5, 2021
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics studyL Cerbone, D Combarel, A Geraud, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 22, 2020
[French ccAFU guidelines - update 2020-2022: management of kidney cancer]K Bensalah, P Bigot, L Albiges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 24, 2024
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upT Powles, L Albiges, A Bex, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 16, 2019
[French ccAFU guidelines - Update 2018-2020: Management of kidney cancer]K Bensalah, L Albiges, J-C Bernhard, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 27, 2018
RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : prise en charge du cancer du reinFrench ccAFU guidelines – Update 2018–2020: Management of kidney cancerK Bensalah, L Albiges, J-C Bernhard, et al.
ESMO Open|April 27, 2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinomaJ B A G Haanen, J Larkin, T K Choueiri, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 16, 2022
Circulating Biomarkers in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus in the Pre-nephrectomy SettingL Mauge, L Phan, N Benhamouda, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 5, 2021
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignanciesF Pommeret, J Colomba, C Bigenwald, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]C Dariane, C Pasqualini, N Gaspar, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 17, 2016
[CCAFU french national guidelines 2016-2018 on renal cancer]K Bensalah, L Albiges, J-C Bernhard, et al.
ESMO Open|December 5, 2021
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics studyL Cerbone, D Combarel, A Geraud, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 22, 2020
[French ccAFU guidelines - update 2020-2022: management of kidney cancer]K Bensalah, P Bigot, L Albiges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 24, 2024
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upT Powles, L Albiges, A Bex, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 16, 2019
[French ccAFU guidelines - Update 2018-2020: Management of kidney cancer]K Bensalah, L Albiges, J-C Bernhard, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 27, 2018
RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : prise en charge du cancer du reinFrench ccAFU guidelines – Update 2018–2020: Management of kidney cancerK Bensalah, L Albiges, J-C Bernhard, et al.
ESMO Open|April 27, 2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinomaJ B A G Haanen, J Larkin, T K Choueiri, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 16, 2022
Circulating Biomarkers in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus in the Pre-nephrectomy SettingL Mauge, L Phan, N Benhamouda, et al.
Pageof 7